Metabolite News and Research

RSS

Metabolites are the intermediates and products of metabolism. The term ''metabolite'' is usually restricted to small molecules.

New genetic signature could cause bile duct cancer

Investigators at the Massachusetts General Hospital (MGH) Cancer Center have identified a new genetic signature associated with bile duct cancer, a usually deadly tumor for which effective treatment currently is limited.

19 Jan 2012

Effects of allopregnanolone in women with severe pre-menstrual syndrome

Sensitivity to allopregnanolone, a hormone that occurs naturally in the body after ovulation and during pregnancy, changes during the course of the menstrual cycle and is different in women with severe pre-menstrual syndrome (PMS) compared with women without PMS complaints. This has been shown by Erika Timby in her doctoral dissertation recently defended at Umeå University, Sweden.

22 Dec 2011

Scientists identify A2bAR as possible new therapeutic target against atherosclerosis

Researchers from Boston University School of Medicine (BUSM) have identified for the first time the A2b adenosine receptor (A2bAR) as a possible new therapeutic target against atherosclerosis resulting from a diet high in fat and cholesterol.

13 Dec 2011

ZIOPHARM receives European patent allowance for palifosfamide to treat cancer

ZIOPHARM Oncology, Inc. announced today that it has received an allowance from the European Patent Office for Patent Application No. 05 821 125.1, entitled "Salts of Isophosphoramide mustard and analogs thereof as anti-tumor agents" with claims directed to pharmaceutical compositions of a novel DNA cross-linker, including palifosfamide and their use in treating cancer.

7 Dec 2011

Concert to initiate CTP-499 Phase 2 diabetic nephropathy clinical trial in 2012

Concert Pharmaceuticals, Inc. today announced data from a Phase 1 clinical trial of CTP-499, a novel agent for the potential treatment of diabetic nephropathy.

14 Nov 2011

Elixir Medical announces initiation of DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System study

Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced enrollment initiation for a 120-patient, international pivotal clinical study to evaluate the safety and efficacy of the DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System designed to resorb in the body within 1 to 2 years after implantation and return the patients' coronary vessel to de novo state.

11 Nov 2011

Health benefits of nut consumption

A recent scientific study has revealed the relationship between nut consumption and a high level of serotonin metabolites (an important neurotransmitter) in patients with metabolic syndrome, who are at high risk of cardiovascular disease.

11 Nov 2011

Aristolochic acid leads to kidney failure, upper urinary tract cancer

Aristolochic acid, a component of a plant used in herbal remedies since ancient times and still used in certain herbal medicines worldwide, leads to kidney failure and upper urinary tract cancer in individuals exposed to the toxin.

10 Nov 2011

Positive top-line results from NPSP558 Phase 3 study on hypoparathyroidism

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today announced positive top-line results from REPLACE, a Phase 3 registration study of NPSP558, the company's bioengineered replica of human parathyroid hormone (rhPTH 1-84), in adult hypoparathyroidism patients.

7 Nov 2011

ZIOPHARM reports promising preclinical data with palifosfamide in pediatric sarcoma model

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced the presentation of promising preclinical data with palifosfamide in a pediatric sarcoma model.

29 Oct 2011

Study provides details on genetics behind many metabolic diseases

In what is so far the largest investigation of its kind, researchers uncovered a wide range of new insights about common diseases and how they are affected by differences between two persons' genes. The results from this study could lead to highly targeted, individualized therapies.

27 Oct 2011

Data from Concert Pharmaceuticals' CTP-499 study to be presented at ASN Kidney Week 2011

Concert Pharmaceuticals, Inc. today announced that three abstracts relating to CTP-499, its clinical candidate for the potential treatment of diabetic nephropathy, have been accepted for poster presentations at the American Society of Nephrology's (ASN) Kidney Week 2011.

19 Oct 2011

International conference on polyphenols and health to be held in Sitges

The 5th International Conference on Polyphenols and Health will bring together over 700 researchers from around the world to discuss the latest findings on the polyphenolic components of food and their role in disease prevention and health promotion.

18 Oct 2011

FDA approves NDA for Edgemont's Fluoxetine 60 mg tablet

Edgemont Pharmaceuticals, LLC, a neuroscience focused company, today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Fluoxetine Tablets 60 mg.

12 Oct 2011

Inhibition of Sab protein protects liver from acetaminophen toxicity

New research from the Keck School of Medicine of the University of Southern California (USC) may help prevent damage to the liver caused by drugs like acetaminophen and other stressors.

8 Sep 2011

Bruker releases new amaZon speed ion trap mass spectrometers

At the HUPO 10th Annual World Congress in Geneva, Switzerland, and at the JAIMA Conference in Tokyo, Japan, Bruker this week announces the release of its new high-performance amaZon speed and amaZon speed ETD ion trap mass spectrometers (ITMS) to meet the increasing demands of the proteomics, research and applied markets.

6 Sep 2011

Soy useless for menopause

In their two year study they found that there were no differences in changes in bone density or menopausal symptoms between women taking soy and those taking a placebo, although women taking isoflavones did have more hot flashes, Dr. Silvina Levis of the University of Miami and colleagues reported in the August 8/22 issue of Archives of Internal Medicine.

8 Aug 2011

BioCryst second quarter total revenues decrease to $3.7 million

BioCryst Pharmaceuticals, Inc. announced financial results for the second quarter and six months ended June 30, 2011.

4 Aug 2011

Anavex presents data on neuroprotective evidence for lead compound for Alzheimer’s

Anavex Life Sciences Corp. is pleased to provide a summary of its second poster presentation at the Alzheimer’s Association International Conference (AAIC) held in Paris, entitled “Preclinical development of new tetrahydrofuran derivatives targeting the sigma-1 chaperone protein as neuroprotectants in Alzheimer’s disease.”

26 Jul 2011

Exposure to tobacco smoke nearly doubles risk of hearing loss among adolescents

NYU School of Medicine researchers report in a new study that exposure to tobacco smoke nearly doubles the risk of hearing loss among adolescents. The study is published in the July, 2011, issue of Archives of Otolaryngology - Head & Neck Surgery.

19 Jul 2011